Trial Profile
An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 10 Sep 2014 New trial record